The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Edwards Lifesciences Corp (NYSE: EW) was $83.1 for the day, down -0.88% from the previous closing price of $83.84. In other words, the price has decreased by -$0.88 from its previous closing price. On the day, 6.29 million shares were traded. EW stock price reached its highest trading level at $83.6 during the session, while it also had its lowest trading level at $81.26.
Ratios:
Our analysis of EW’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 59.96. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 4.00. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
On December 18, 2025, JP Morgan Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $100.
Raymond James Upgraded its Mkt Perform to Outperform on November 03, 2025, while the target price for the stock was maintained at $96.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 09 ’26 when Lippis Daniel J. sold 1,019 shares for $85.70 per share. The transaction valued at 87,332 led to the insider holds 22,002 shares of the business.
BOBO DONALD E JR sold 11,340 shares of EW for $971,429 on Jan 06 ’26. The CVP,Strategy/Corp Development now owns 31,870 shares after completing the transaction at $85.66 per share. On Jan 06 ’26, another insider, BOBO DONALD E JR, who serves as the Officer of the company, bought 45,360 shares for $85.66 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 48788013056 and an Enterprise Value of 45142429696. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 35.38, and their Forward P/E ratio for the next fiscal year is 28.68. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.87. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.20 while its Price-to-Book (P/B) ratio in mrq is 4.73. Its current Enterprise Value per Revenue stands at 7.672 whereas that against EBITDA is 25.242.
Stock Price History:
The Beta on a monthly basis for EW is 0.94, which has changed by 0.20011449 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, EW has reached a high of $87.89, while it has fallen to a 52-week low of $65.94. The 50-Day Moving Average of the stock is -2.12%, while the 200-Day Moving Average is calculated to be 5.80%.
Shares Statistics:
EW traded an average of 3.93M shares per day over the past three months and 3231700 shares per day over the past ten days. A total of 580.70M shares are outstanding, with a floating share count of 572.37M. Insiders hold about 1.37% of the company’s shares, while institutions hold 87.49% stake in the company. Shares short for EW as of 1767139200 were 7138485 with a Short Ratio of 1.81, compared to 1764288000 on 6980005. Therefore, it implies a Short% of Shares Outstanding of 7138485 and a Short% of Float of 1.39999995.
Earnings Estimates
Edwards Lifesciences Corp (EW) is currently under the scrutiny of 27.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.68, with high estimates of $0.73 and low estimates of $0.64.
Analysts are recommending an EPS of between $2.63 and $2.41 for the fiscal current year, implying an average EPS of $2.58. EPS for the following year is $2.89, with 31.0 analysts recommending between $3.12 and $2.65.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 27 analysts. It ranges from a high estimate of $1.6B to a low estimate of $1.5B. As of. The current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.39BFor the next quarter, 27 analysts are estimating revenue of $1.57B. There is a high estimate of $1.6B for the next quarter, whereas the lowest estimate is $1.54B.
A total of 32 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.1B, while the lowest revenue estimate was $5.89B, resulting in an average revenue estimate of $6.03B. In the same quarter a year ago, actual revenue was $5.44BBased on 32 analysts’ estimates, the company’s revenue will be $6.62B in the next fiscal year. The high estimate is $6.77B and the low estimate is $6.39B.
